Sugi Predict

Sugi Predict / Compounds / SCHEMBL2720165

SCHEMBL2720165

SCHEMBL2720165

CCOC(=O)CP(=O)(OC(C)C)OC(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAM O43451 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ SI P14410 1/20 0.43
▸ MGAM2 Q2M2H8 1/20 0.43
▸ ALDH1A1 P00352 6/20 0.40
▸ TRPA1 O75762 1/20 0.40
▸ CTSA P10619 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ ALOX15 P16050 3/20 0.38
▸ TSHR P16473 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ CYP1A2 P05177 1/20 0.35
▸ HSD17B10 Q99714 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ CHRM1 P11229 1/20 0.33
▸ ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7845583 0.91 TSHR (0.39) MGAMGAASIMGAM2ALDH1A1
SCHEMBL8715424 0.79 LMNA (0.39) ALDH1A1CTSAACHETSHRTDP1
SCHEMBL2717779 0.79 POLB (0.40) MGAMGAASIMGAM2ALDH1A1
SCHEMBL15439045 0.78 ACHE (0.36) CTSAACHETSHRL3MBTL1
SCHEMBL18759661 0.77 TSHR (0.48) MGAMGAASIMGAM2ALDH1A1
SCHEMBL16047 0.77 TSHR (0.48) MGAMGAASIMGAM2ALDH1A1
SCHEMBL639641 0.77 GAA (0.48) MGAMGAASIMGAM2ALDH1A1
SCHEMBL1331297 0.77 TSHR (0.48) MGAMGAASIMGAM2ALDH1A1
SCHEMBL4327885 0.77 TSHR (0.36) MGAMGAASIMGAM2ALDH1A1
SCHEMBL1564812 0.76 TSHR (0.39) CTSAACHETSHRTDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives GLAXO GROUP LIMITED (GB) 2008-04-24 — — US claimed
EP-1865959-A2 PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2007-12-19 — — EP claimed
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives GLAXO GROUP LIMITED (GB) 2006-11-16 — — US claimed
WO-2006104917-A2 PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2006-10-05 — — WO claimed
US-20180198166-A1 NON-AQUEOUS ELECTROLYTE AND POWER STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD. (JP) 2018-07-12 — — US disclosed
US-9966632-B2 Non-aqueous electrolyte and power storage device using same UBE INDUSTRIES, LTD. (JP) 2018-05-08 — — US disclosed
US-9318776-B2 Nonaqueous electrolyte solution and electricity storage device using same UBE INDUSTRIES, LTD. (JP) 2016-04-19 — — US disclosed
US-9318776-B2 Nonaqueous electrolyte solution and electricity storage device using same UBE INDUSTRIES, LTD. (JP) 2016-04-19 — — US disclosed
US-20150333370-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTRICITY STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD. (JP) 2015-11-19 — — US disclosed
US-20150333370-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTRICITY STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD. (JP) 2015-11-19 — — US disclosed
US-20150221985-A1 NON-AQUEOUS ELECTROLYTE AND POWER STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD. (JP) 2015-08-06 — — US disclosed
US-20150221985-A1 NON-AQUEOUS ELECTROLYTE AND POWER STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD. (JP) 2015-08-06 — — US disclosed
US-6946481-B1 Endothelin antagonists ABBOTT LABORATORIES (US) 2005-09-20 — — US disclosed
EP-0807112-B1 HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS UPJOHN CO (US) 2001-09-05 — — EP disclosed
US-6284910-B1 FARNESYL TRANSFERASE INHIBITORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2001-09-04 — — US disclosed
US-6124334-A A BACTERICIDE TREATING INFECTIONS CAUSED BY GRAM-POSITIVE AEROBIC BACTERIA SUCH AS STAPHYLOCOCCUS, STREPTOCOCCUS AND ENTEROCOCCUS AS WELL AS ANAEROBIC ORGANISMS SUCH AS BACTEROIDES AND CLOSTRIDIUM AND MYCOBACTERIDIUM PHARMACIA & UPJOHN COMPANY (US) 2000-09-26 — — US disclosed
US-5910504-A BACTERICIDES TREATING INFECTIONS PHARMACIA & UPJOHN (US) 1999-06-08 — — US disclosed
EP-0807112-A1 HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS PHARMACIA & UPJOHN COMPANY (US) 1997-11-19 — — EP disclosed
US-5414078-A Preparation of 3'-substituted-2',3'-dideoxynucleosides and 2'-deoxynucleosides from acyclic, achiral precursors EMORY UNIVERSITY (US) 1995-05-09 — — US disclosed
US-4798799-A HYPHOZYMA YEAST FRITZSCHE DODGE & OLCOTT INC. (US) 1989-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives CBR3, CBR1, CYP2S1 MGAM 4868/4885GAA 4688/4885SI 3923/4885
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives CYP2S1, CYP2F1, CBR3 MGAM 4857/4885GAA 4657/4885SI 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.